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PPRECLINICAL RESEARCH
Design, Synthesis, and Actions
of a Novel Chimeric Natriuretic Peptide: CD-NP
Ondrej Lisy, MD, PHD,* Brenda K. Huntley,* Daniel J. McCormick, PHD,† Paul A. Kurlansky, MD,‡
John C. Burnett, JR, MD*
Rochester, Minnesota; and Miami, Florida
Objectives Our aim was to design, synthesize and test in vivo and in vitro a new chimeric peptide that would combine the
beneficial properties of 2 distinct natriuretic peptides with a biological profile that goes beyond native peptides.
Background Studies have established the beneficial vascular and antiproliferative properties of C-type natriuretic peptide
(CNP). While lacking renal actions, CNP is less hypotensive than the cardiac peptides atrial natriuretic peptide
and B-type natriuretic peptide but unloads the heart due to venodilation. Dendroaspis natriuretic peptide is a
potent natriuretic and diuretic peptide that is markedly hypotensive and functions via a separate guanylyl cy-
clase receptor compared with CNP.
Methods Here we engineered a novel chimeric peptide CD-NP that represents the fusion of the 22-amino acid peptide
CNP together with the 15-amino acid linear C-terminus of Dendroaspis natriuretic peptide. We also determined
in vitro in cardiac fibroblasts cyclic guanosine monophosphate-activating and antiproliferative properties of
CD-NP.
Results Our studies demonstrate in vivo that CD-NP is natriuretic and diuretic, glomerular filtration rate enhancing, car-
diac unloading, and renin inhibiting. CD-NP also demonstrates less hypotensive properties when compared with
B-type natriuretic peptide. In addition, CD-NP in vitro activates cyclic guanosine monophosphate and inhibits car-
diac fibroblast proliferation.
Conclusions The current findings advance an innovative design strategy in natriuretic peptide drug discovery and develop-
ment to create therapeutic peptides with favorable properties that may be preferable to those associated with
native natriuretic peptides. (J Am Coll Cardiol 2008;52:60–8) © 2008 by the American College of Cardiology
Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.02.077a
c
(
m
t
a
f
c
f
m
t
a
C
m
(
C
(
an emerging innovative therapeutic strategy is the engi-
eering of proteins, which fuses structural elements unique
or 1 peptide with active structures from separate peptides to
reate chimeras, which possess attractive therapeutic prop-
See page 69
rties (1). Such an approach with natriuretic peptides is
dvanced in the current study and involves the selection and
ncorporation of isolated structural determinants from 2
ative peptides that result in a unique peptide with a specific
rom the *Cardiorenal Research Laboratory, Division of Cardiovascular Diseases,
nd †Laboratory of Expression Proteomics and Protein Chemistry, Mayo Clinic and
ayo Clinic College of Medicine, Rochester, Minnesota; and the ‡Miami Heart
esearch Institute, Miami, Florida. This study was supported by Mayo Foundation
nd grants from the Miami Heart Research Institute and National Institutes of
ealth (RO1HL36634, PO1HL76611, and R01HL8373). CD-NP has been li-
ensed by the Mayo Clinic to Nile Therapeutics and Dr. Burnett is Chair of its
cientific Advisory Board.b
Manuscript received December 27, 2007; revised manuscript received February 19,
008, accepted February 26, 2008.ctivity profile that could be more useful than their natural
ounterparts as therapeutic agents in cardiorenal disease.
C-type natriuretic peptide (CNP) is a 22-amino acid
AA) peptide that shares structural homology with other
embers of the natriuretic peptide family, which includes
he cardiac hormones atrial natriuretic peptide (ANP)
nd B-type natriuretic peptide (BNP), all of which
unction via well-characterized particulate guanylyl cy-
lase receptors (i.e., NPR-A for ANP and BNP; NPR-B
or CNP) and the second messenger cyclic 3=5= guanosine
onophosphate (cGMP) (2– 4). While possessing struc-
ural similarity, CNP is genetically distinct from ANP
nd BNP. Also unlike ANP or BNP, CNP lacks a
OOH-terminus (C-terminus) AA extension, which
ay explain, in part, its lack of natriuretic properties
5,6). Since its discovery in 1990, we have learned that
NP is principally an endothelial cell-derived peptide
7–13). In isolated venous and arterial rings, CNP
ctivates NPR-B receptors in veins while ANP and BNP
ind to NPR-A receptors in both arteries and veins,
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July 1, 2008:60–8 CD-NP: A Novel Chimeric Natriuretic Peptidehich is consistent with the less hypotensive actions of
NP as compared with ANP and BNP (14 –16).
In addition to preferential venodilating properties, studies
ave also reported that CNP possesses more potent anti-
roliferative and collagen-suppressing properties in cardiac
broblasts (CFs) as compared with ANP and BNP (11).
elevant to such fibro-inhibiting properties, studies have
hown that 14 days of continuous infusion of CNP in
odents with acute myocardial infarction (AMI) markedly
ttenuates ventricular dilation, cardiac fibrosis, and cardio-
yocyte hypertrophy (17). The chronic infusion of CNP
as without any hypotensive actions.
In clear contrast to ANP and BNP, CNP lacks significant
atriuretic and diuretic actions when infused into humans.
his may explain its lack of utility in sodium- and water-
etaining syndromes such as acute heart failure (AHF)
espite its attractive venodilating and antifibrotic properties
15,16).
In 1992, Schweitz et al. (18) reported the in vitro
iological actions of a newly discovered peptide Dendroaspis
atriuretic peptide (DNP). We subsequently reported that
NP, which was originally isolated from the green mamba,
as in vivo potently natriuretic and diuretic and possessed
ardiac unloading actions but with significant hypotensive
roperties (19,20). In the original report of the vasoactive
ctions of DNP, Schweitz et al. (18) concluded that DNP,
ike ANP and BNP, functions via the NPR-A receptor as
aturation with ANP markedly attenuated the cGMP-
ctivating actions of DNP in cultured human endothelial
ells. Indeed, the in vivo actions of DNP that include
atriuresis and hypotension are consistent with NPR-A
ctivation as such effects closely mimic the properties of
NP and BNP but not CNP. Indeed, Singh et al. (21)
ecently have reported that DNP has a higher affinity for the
PR-A receptor in human myocardium as compared with
NP and BNP.
A key structural feature of DNP is that it possesses the
ongest C-terminus of the known natriuretic peptides con-
isting of 15 AA as compared with 5 AA for ANP, 6 AA for
NP and none for CNP. Indeed, the long C-terminus of
NP may render DNP highly resistant to degradation by
eutral endopeptidase (NEP) contributing to potent natri-
retic and diuretic actions (22). Further, the lack of a
-terminus for CNP may explain the observation that of
he 3 known endogenous natriuretic peptides CNP is the
ost susceptible to NEP degradation, which could limit its
enal actions as NEP is expressed greatest in the kidney (23).
Based upon exploratory studies of the 15-AA C-terminus
f DNP, we hypothesized that fusion of the 15-AA
-terminus of DNP into the C-terminus position of the
ore 22-AA ring structure of CNP would result in a
ynthetic chimeric peptide that in vivo would possess the
ardiac unloading actions of CNP with minimal hypoten-
ive properties together with the additional renal effects of
atriuresis and diuresis. We also hypothesized that this
himera called CD-NP would retain properties of CNP in citro in activating cGMP in CFs
nd inhibiting cell proliferation.
hus, we report the design, pro-
ein synthesis, and biological ac-
ions of a chimeric natriuretic
eptide with potentially benefi-
ial efficacy and safety for the
reatment of cardiorenal diseases
tates such as AHF and AMI.
ethods
e synthesized 2 peptides based
pon the known sequence of DNP
nd CNP. First we synthesized the
inear 15-AA C-terminus se-
uence (PSLRDPRPNAPSTSA)
f DNP (Fig. 1). We call this
eptide “C-terminus.” Secondly,
e designed and synthesized a chi-
era of CNP and the C-terminus
f DNP (GLSKGCFGLKL-
RIGSMSGLGCPSLRDPRP-
APSTSA), which is a 37-AA
eptide that we call “CD-NP.”
hese 2 peptides were synthesized
sing solid phase methods by the
ayo Protein Core Facility on an
BI 431A Peptide Synthesizer
PE Biosystems, Foster City, Cal-
fornia) on a pre-loaded Wang
esin with N-Fmoc-L-amino acids (SynPep, Dublin, Califor-
ia). Coupling of each AA to the resin-linked peptide was
erformed in 1-methyl-2-pyrrolidinone (NMP) for 40 min.
ach Fmoc AA was activated in a solution of
-hydroxybenzotriazole in NMP for 30 min. Deprotection of
he Fmoc protecting group was performed with 20% piperi-
ine in NMP for 20 min before coupling of the next activated
A. Subsequently, peptides were deprotected and removed
rom the resin by treatment with a mixture of 82.5% trifluoro-
cetic acid/5% water/5% thioanisole/2.5% ethanedithiol/5%
henol for 2 h at room temperature. Each peptide was washed
y precipitation in 3 50 ml of cold methyl t-butyl ether and
urified by reverse phase high performance liquid chromatog-
aphy on a Jupiter C18 column (Phenomenex, Torrance,
alifornia) in 0.1% trifluoroacetic acid/water with a
radient of 10% to 70% B in 50 min.
The identity of each peptide was verified by electrospray
onization mass analysis on a Perkin/Elmer Sciex API 165
ass Spectrometer (PE Biosystems). Disulfide bridges in
D-NP were formed by overnight air oxidation in a 50 mM
mmonium bicarbonate pH 8.5 buffer.
ntegrative in vivo biological actions of C-terminus and
D-NP in normal canines. Experiments were performed
n 5 separate groups of normal anesthetized dogs. All studies
Abbreviations
and Acronyms
AA  amino acid
AHF  acute heart failure
AMI  acute myocardial
infarction
ANP  atrial natriuretic
peptide
BNP  B-type natriuretic
peptide
BrdU  bromodeoxyuridine
CF  cardiac fibroblast
cGMP  cyclic 3=5=
guanosine monophosphate
CNP  C-type natriuretic
peptide
DNP  Dendroaspis
natriuretic peptide
GFR  glomerular filtration
rate
NEP  neutral
endopeptidase
NMP 
1-methyl-2-pyrrolidinone
PFRNa  proximal
fractional sodium
reabsorption
PRA  plasma renin
activityonformed to the guidelines of the American Physiological
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nd Use Committee.
On the evening before the experiments, 300 mg of
ithium carbonate was administered orally for the assess-
ent of segmental renal tubular function and then dogs
ere fasted overnight. On the day of the acute experiment,
ll dogs were anesthetized with pentobarbital sodium given
ntravenously (30 mg/kg). Dogs were mechanically venti-
ated (Harvard respirator, Harvard Apparatus, Millis, Mas-
achusetts) with 4 l/min of supplemental oxygen. A left
ateral flank incision was made, and the left kidney was
xposed. The ureter was cannulated for timed urine collec-
ion, and a calibrated electromagnetic flow probe was placed
round the left renal artery and connected to a flowmeter
model FM 5010, Carolina Medical, King, North Carolina)
or monitoring of renal blood flow. Finally, the right
emoral vein was cannulated with 2 polyethylene catheters
PE-240), 1 for infusion of inulin and the other for the
nfusion of C-terminus. The right femoral artery was
annulated for direct arterial blood pressure measurement
nd arterial blood sampling. For determination of cardiac
lling pressures in those groups that received CD-NP or
NP and measurement of cardiac output, a Swan-Ganz
atheter (Edwards, Mountain View, California) was in-
erted into the right internal jugular vein.
After completion of the surgical preparation, a priming
ose of inulin (ICN Biomedicals, Cleveland, Ohio) was
njected, followed by a constant infusion of 1 ml/min. The
ogs were allowed to equilibrate for 60 min without
ntervention. After an equilibration period of 60 min, a
0-min baseline clearance (Baseline) was performed. This
as followed by a 15-min lead-in period during which
-terminus infusion at 42 ng/kg/min in the first group (n
) was begun intravenously after which the second 30-min
learance (C-terminus) period was performed. A time
Figure 1 AA Sequence and Structure of a CNP and Novel Chim
C-type natriuretic peptide (CNP) is a 22-amino acid (AA) endothelial-cell-derived nat
Dendroaspis natriuretic peptide (DNP) is a 15-AA chimeric natriuretic peptide, andontrol with intravenous saline at 1 ml/min (n  6) was aerformed to serve as a control for the CD-NP group.
uring each clearance, renal hemodynamic and excretory
esponse was recorded. In the third group, CD-NP was
nfused at 3 concentrations that were 10, 50, and 100
g/kg/min each for 30 min with a 15-min lead-in period for
ach dose. Groups 4 (n  6) and 5 (n  6) received an
quimolar concentration of 10 and 50 ng/kg/min of
D-NP or BNP, respectively.
Plasma and urine electrolytes including lithium were
easured by flame-emission spectrophotometer (IL943,
lame Photometer, Instrumentation Laboratory, Lexing-
on, Massachusetts). Plasma and urine inulin concentrations
ere measured by the anthrone method, and glomerular
ltration rate (GFR) was measured by the clearance of
nulin. The lithium clearance technique was employed to
stimate the proximal fractional sodium reabsorption
PFRNa) and distal fractional sodium reabsorption. Proxi-
al fractional sodium reabsorption was calculated by the
ollowing formula: [1  (lithium clearance/GFR)]  100.
istal fractional sodium reabsorption was calculated by the
ormula: [(lithium clearance  sodium clearance)/lithium
learance]  100. Plasma and urinary cGMP and plasma
enin activity (PRA) were measured by commercially avail-
ble radioimmunoassay as described previously.
n vitro studies on CD-NP cGMP generation and
nhibition of cell proliferation in human CFs. Studies
ere performed in human CFs (ScienCell, San Diego,
alifornia) as we have previously reported (24). Only cell
assages 1 through 4 were used for experiments. Cells were
xposed to CD-NP (1011 to 106 M) for 15 min to
etermine cGMP activation. The samples were assayed
sing a competitive radioimmunoanalysis cGMP kit
Perkin-Elmer, Boston, Massachusetts). Briefly, samples
nd standards were incubated with anti-human cGMP
olyclonal antibody and I125-antigen for 18 h. Cyclic GMP
atriuretic Peptide C-Terminus of DNP and CD-NP
c peptide, C-terminus of
is a 37-AA-designed chimeric natriuretic peptide.eric N
riureti
CD-NPssay buffer was added to the samples, and they were
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July 1, 2008:60–8 CD-NP: A Novel Chimeric Natriuretic Peptideentrifuged for 20 min at 2,500 rpm. The free fraction was
spirated off, and the bound fraction was counted and
oncentrations determined. Values are expressed as pmoles/
l. There was no cross-reactivity with ANP, BNP, CNP,
nd endothelin, and 0.001% cross-reactivity with cyclic
denosine monophosphate, GMP, guanosine diphosphate,
denosine triphosphate, and guanosine triphosphate.
For CFs proliferation studies, 70% to 80% confluent cells
t passage 1 to 4 cells were treated for 24 h with 108 M
ardiotrophin-1 to induce cell proliferation. CD-NP at the
oncentration of 108 M was added to cardiotrophin-1-
timulated CFs to determine its effect on cell proliferation.
ntreated fibroblasts were processed as a control. Color-
etric bromodeoxyuridine (BrdU) cell proliferation
nzyme-linked immunoadsorbent assay (Roche, Indiana-
olis, Indiana) was performed as directed. Briefly, CFs were
abeled with BrdU for 2 h in a CO2 37°C incubator.
ntibromodeoxyuridine was added and allowed to react for
0 min at room temperature. The anti-BrdU was removed,
nd the CFs were washed 3 times with a washing solution.
olormetric substrate solution was added, and color was
llowed to develop for 30 min. Absorbance at 370 nm was
easured on a SpectraMax spectrophotometer (Molecular
evices, Sunnyvale, California).
tatistical analysis. Results of quantitative studies are ex-
ressed as mean  SE. Statistical comparisons within 1
roup when comparing 2 clearances was performed using
tudent t test, and when comparing multiple clearances,
epeated measures analysis of variance (ANOVA) followed
y post hoc Dunnett’s test. Statistical comparison between
roups was performed using 2-way ANOVA followed by
onferroni post-test. Statistical significance was accepted
or a p value 0.05.
esults
n vivo actions of C-terminus of DNP and CD-NP. The
-terminus of DNP that is lacking the core ring structure of
NP was natriuretic and diuretic (Fig. 2). We localized this
atriuretic action to the proximal segment of the renal
ephron as we observed a decrease in PFRNa suggesting
hat this part of the nephron contributes to the renal actions
f this small peptide (Table 1). We noted no change in
FR, renal blood flow, or urinary cGMP excretion. Impor-
antly, in a time control group that also received saline at 1
l/min as in the C-terminus group, parameters of renal
unction were unchanged (data not shown).
Figure 3 reports the in vivo responses to CD-NP infu-
ion. All 3 doses of CD-NP decreased pulmonary capillary
edge pressure while 2 doses decreased right atrial pressure.
hese cardiac unloading responses were associated with
inimal decreases in mean arterial pressure even during the
nfusion of a high dose of CD-NP. We also observed potent
atriuretic and diuretic responses with CD-NP in normal
anines (Fig. 4). Specifically, both medium and high dose
D-NP increased urinary excretion of sodium and urine gow (Fig. 4). Despite a slight decrease in mean arterial
ressure during the infusion of a high dose of CD-NP,
FR increased. There was no change in renal blood flow
uring CD-NP infusion (240  40 ml/min [baseline] to
45  27 ml/min [dose-10] to 248  25 ml/min [dose-50]
o 253  22 ml/min [dose-100] and to 221  32 ml/min
recovery]). Natriuresis and diuresis involved a decrease in
roximal tubular reabsorption of sodium as PFRNa during
he infusion of medium dose of CD-NP was reduced. In
ddition, a decrease in distal fractional sodium reabsorption
uring the infusion of medium and high doses of CD-NP
as also observed, which indicates that CD-NP also in-
olves activities in the terminal nephron (Fig. 5). These
enal parameters returned to baseline levels after discontin-
ation of the infusion of CD-NP. These actions were also
ssociated with suppression of PRA during the infusion of
ow and medium doses of CD-NP (Table 2). Plasma renin
ctivity returned to baseline levels after discontinuation of
nfusion. Medium and high doses of CD-NP increased
lasma and urinary cGMP (Table 2).
At a dose of 50 ng/kg/min, CD-NP significantly in-
reased GFR in contrast to a lack of increase in GFR in the
Figure 2 Effect of C-Terminus of DNP
on UNaV and UV in Normal Dogs
Data are expressed as means  SE. C-terminus, intravenous infusion of 42
ng/kg/min of C-terminus, n  6. *p  0.05 versus baseline. DNP  Den-
droaspis natriuretic peptide; UNaV  urinary excretion of sodium; UV  urine
flow.roup receiving an equimolar dose of BNP (Fig. 6). Impor-
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CD-NP: A Novel Chimeric Natriuretic Peptide July 1, 2008:60–8antly, this dose of CD-NP was associated with a less
ypotensive action than BNP.
D-NP–mediated cGMP generation in CFs and inhibi-
ion of proliferation. Figure 7 reports findings from in
itro studies in cultured human CFs. These studies demon-
trate that CD-NP activates cGMP in a dose-dependent
anner (Fig. 7A). Further, when compared with CNP,
NP, and DNP, the cGMP generated with CD-NP was
imilar to CNP and significantly greater (p  0.05) than
NP and BNP at 106 M (data not shown). We then
ought to define if CD-NP possessed antiproliferative
ctions. We utilized the pro-fibrotic and hypertrophic
ytokine cardiotrophin-1 that has been reported by others
nd ourselves as a markedly robust activator of CFs and
hich is activated in states such as AMI and heart failure
25–27). CD-NP suppressed cell proliferation in human
Fs induced by cardiotrophin-1 as assessed by BrdU uptake
s a measure of DNA synthesis and cellular proliferation
Fig. 7B).
iscussion
ere we report the design, protein synthesis, and in vivo
ardiorenal actions of a chimeric natriuretic peptide that is a
usion of the core 22-AA ring structure of CNP together
ith the 15-AA C-terminus of DNP. Unlike CNP, which
acks significant renal actions, CD-NP is potently natri-
retic and diuretic, GFR enhancing, and PRA inhibiting.
D-NP reduces cardiac filling pressures and when com-
ared with BNP is less hypotensive. In vitro studies in
ultured CFs establish that CD-NP, like CNP, activates
GMP and suppresses CF proliferation induced by
ardiotrophin-1, which is known to be activated in heart
ailure and myocardial infarction. This modular design
ncorporating sequences of 2 native peptides thus emerges as
ttractive from a therapeutic standpoint as many of the
urrent native natriuretic peptides for the treatment of AHF
nd AMI such as ANP and BNP optimize 1 function such
s cardiac unloading while sacrificing another such as
aintenance of blood pressure, which is overcome by
D-NP.
The current study also demonstrates that the chimeric
enal Hemodynamic and Excretorysponse t Infusion of C-Terminus
Table 1 Renal Hemodynamic and ExcretoryResponse to Infusion of C-Terminus
Baseline C-Terminus
GFR (ml/min) 34 6 44 6
RBF (ml/min) 213 19 198 27
PFRNa (%) 77.9 2.7 71.0 2.6*
DFRNa (%) 98.7 0.3 97.8 0.5
UcGMPV (pmol/min) 1,674 213 2,275 231
ata are expressed as means  SE. p  0.05 versus baseline.
C-terminus infusion of 42 ng/kg/min of C-terminus of Dendroaspis natriuretic peptide (n 6);
FRNa  distal fractional sodium reabsorption; GFR  glomerular filtration rate; PFRNa 
roximal fractional sodium reabsorption; RBF  renal blood flow; UcGMPV  urinary cyclic 3=5=
uanosine monophosphate excretion.eptide CD-NP, which combines the full-length 22 AAing structure of CNP with the 15 AA C-terminus of DNP,
s potently natriuretic and diuretic and GFR enhancing,
hich is in contrast to the reported lack of significant renal
ctions of CNP (5,15,16). The natriuretic action of CD-NP
as localized to both the proximal and distal nephrons.
ontributing to the natriuretic and diuretic action of
D-NP was an increase in GFR. The increase in GFR,
herefore, must be mediated by a decrease in pre-glomerular
ascular resistance together with an increase in post-
lomerular vascular tone to increase glomerular capillary
ydrostatic pressure while there was no significant change
n renal blood flow. Alternatively, an increase in the
lomerular ultrafiltration coefficient (Kf) could contribute
Figure 3 Effect of CD-NP on MAP,
RAP, and PCWP in Normal Dogs
Data are expressed as means  SE. n  6. *p  0.05 versus baseline.
CD-NP 10  dose of CD-NP 10 ng/kg/min; CD-NP 50  dose of CD-NP 50
ng/kg/min; CD-NP 100  dose of CD-NP 100 ng/kg/min; MAP  mean arterial
pressure; PCWP  pulmonary capillary pressure; RAP  right atrial pressure.
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July 1, 2008:60–8 CD-NP: A Novel Chimeric Natriuretic Peptideo the GFR increase. Importantly, we observed that the
enal hemodynamic and tubular actions of CD-NP were
ssociated with increases in plasma and urinary cGMP
oncentrations consistent with particulate guanylyl cy-
lase receptor activation.
In the past, we and others have speculated that under
hysiologic condition renally synthesized CNP acts in an
utocrine/paracrine fashion to activate NPR-B receptors,
hich are expressed in the kidney, resulting in natriuretic
nd diuretic actions (28–32). This would be in contrast to
ntravenously infused CNP, which lacks significant renal
ctions due to rapid degradation by renal NEP. It is
empting to speculate that the addition of the C-terminus of
Figure 4 Effect of CD-NP on UNaV,
UV, and GFR in Normal Dogs
Data are expressed as means  SE. n  6. *p  0.05 versus baseline.
GFR  glomerular filtration rate; other abbreviations as in Figures 2 and 3.NP protects CNP from degradation by NEP resulting innhanced NPR-B activation by CD-NP that then could
ediate increases in GFR together with natriuresis and
iuresis. Of note, addition of AAs to the C-terminus of
NP has been demonstrated to increase ANP stability by
ncreasing resistance to NEP degradation (33). This concept
ould be consistent with reports that inhibition of NEP
uring DNP administration potentiates the renal actions of
NP, which is observed during administration of native
NP or BNP together with NEP inhibition (22,34,35). It
s also possible that this linear peptide (i.e., C-terminus of
NP) could retard the degradation of endogenous ANP or
NP by competing with NEP and/or reduce binding of the
ative natriuretic peptides to the natriuretic peptide clear-
nce receptor (i.e., NPR-C) making more endogenous ANP
nd BNP available for NPR-A binding in the kidney.
inally, it is possible that the C-terminus of DNP also
ltered the ability of CNP to activate NPR-A directly,
aking CD-NP an NPR-B and NPR-A agonist. Clearly,
D-NP is natriuretic, diuretic, and GFR enhancing with
ess hypotensive actions but by mechanisms that will need to
Figure 5 Effect of CD-NP on Proximal and Distal
Fractional Sodium Reabsorption in Normal Dogs
Data are expressed as means  SE. n  6. *p  0.05 versus baseline.
DFRNa  distal fractional sodium reabsorption; PFRNa  proximal fractional
sodium reabsorption; other abbreviations as in Figure 3.
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CD-NP: A Novel Chimeric Natriuretic Peptide July 1, 2008:60–8e addressed in future studies. It should be noted that at the
ower doses of CD-NP, PRA was suppressed.
CD-NP unloaded the normal heart with reductions in
oth right atrial pressure and pulmonary capillary wedge
ressure. At the doses employed in the normal dogs, cardiac
nloading occurred with no or only modest changes in
rterial pressure. These are consistent with the conclusion
hat the reduction in cardiac filling pressures may involve
eductions in cardiac pre-load via venodilation as occurs
ith CNP (14). Thus, CD-NP may address the need of a
ardiac unloading natriuretic peptide with renal-enhancing
ctions with less hypotension than ANP or BNP, thus
etter maintaining renal function, which was the goal of our
ngineered chimeric peptide.
Figure 6 Effect of CD-NP and Equimolar Doses
of Human BNP in 2 Groups of Normal Dogs
Data are expressed as means  SE. n  6 in each group. *p  0.05 versus
baseline; †p  0.05 between groups. Solid bars  CD-NP; open bars  B-type
natriuretic peptide (BNP). Abbreviations as in Figures 3 and 4.
eurohumoral Response to Infusion of CD-NP in Normal Dogs
Table 2 Neurohumoral Response to Infusion of CD-NP in Norma
Baseline CD-NP 10
PcGMP (pmol/ml) 9.4 1.2 14.6 1.6
UcGMPV (pmol/min) 1,648 151 2,133 234
PRA (ng/ml/hr) 8.2 0.8 5.3 1.1*
ata are expressed as means  SE. p  0.05 versus baseline.
CD-NP 10  infusion of 10 ng/kg/min of CD-NP; CD-NP 50  infusion of 50 ng/kg/min of CD-N
=5= guanosine monophosphate; PRA  plasma renin activity; UcGMPV  urinary cyclic 3=5= guaAn important property of CNP and the natriuretic
eptides is antifibrotic actions in the heart and other organs,
hich involve inhibition of fibroblast proliferation and
uppression of collagen synthesis. Importantly, Horio et al.
11) demonstrated that CNP was more antifibrotic in
ultured human CFs as compared with ANP or BNP. Such
bro-inhibiting actions have clinical relevance as demon-
trated by studies of Soeki et al. (17) in which chronic CNP
nfusion in a rodent model of AMI for 14 days suppressed
Figure 7 Effect of CD-NP on cGMP Generation and
Antiproliferative Actions of CD-NP in Human CFs
(A) Cyclic 3=5= guanosine monophosphate (cGMP) generation in human cardiac
fibroblasts (CFs). Data are expressed as means  SE. *p  0.05 versus no
treatment; **p  0.05 versus CP-NP 1011M; p  0.05 versus CD-NP 108
M. (B) Antiproliferative actions of CD-NP in human CFs. Bar graph reports col-
ormetric bromodeoxyuridine (BrdU) uptake in optical density units as measured
by colorimetry. Data are expressed as means  standard error. *p  0.05 ver-
sus control. Cardiotrophin-1  proliferation of fibroblasts by cardiotrophin-1;
Cardiotrophin-1  CD-NP  CD-NP added to cardiotrophin-1 stimulated fibro-
blasts; Control  untreated human cardiac fibroblasts.
s
CD-NP 50 CD-NP 100 Recovery
30.3 2.1* 50.1 2.1* 32.7 6.7*
4,566 621* 9,999 1,590* 6,661 734*
3.9 0.7* 6.3 1.1 9.0 1.8
P 100  infusion of 100 ng/kg/min (n  8 except n  6 for high dose); PcGMP  plasma cyclic
monophosphate excretion.l Dog
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July 1, 2008:60–8 CD-NP: A Novel Chimeric Natriuretic Peptideentricular remodeling and fibrosis with reductions in col-
agen III synthesis in the absence of reductions in blood
ressure. In our in vitro studies in human CFs, we observed
hat CD-NP activated cGMP and possessed antiprolifera-
ive actions to cardiotropin-1, which is a potent pro-fibrotic
actor that is known to be activated in heart failure and AMI
25–27). This action of CD-NP was demonstrated by
nhibition of cardiotropin-1 augmentation of BrdU uptake.
o further understand mechanisms by which CD-NP is
ntifibrotic, future studies will investigate collagen turnover
n CFs in response to fibrogenic cytokines.
The natriuretic peptide BNP was approved in 2002 as a
ew drug for the treatment of acute decompensated heart
ailure based upon the randomized trial VMAC (The
asodilation in the Management of Acute CHF) which
emonstrated that, compared with nitroglycerin, BNP was
uperior in reducing cardiac filling pressures and compared
ith placebo was superior in improving dyspnea (36). With
ontinued use of BNP, concerns were raised regarding renal
unction with a key study reporting a lack of action of BNP
n kidney function in human heart failure and even a
orsening of renal function (37,38). As the level of GFR is
robust predictor of survival in heart failure, preservation of
enal function or even improvement of renal function is a
igh priority (39,40). We have previously reported that
xperimental reductions in renal perfusion pressure by
uprarenal aortic constriction abolished ANP-mediated in-
reases in GFR and sodium excretion underscoring the
mportance of maintaining renal perfusion pressure in heart
ailure during infusion of natriuretic peptides (41). Indeed,
n recent human studies in heart failure and during cardiac
ypass surgery, low-dose BNP without hypotension has
een demonstrated (42–44). Further, the chronic intermit-
ent use of BNP in human heart failure was unassociated
ith any worsening of renal function compared with pla-
ebo. While further studies in disease states are warranted,
D-NP represents a novel therapeutic strategy, which
ossesses properties of a peptide-like BNP and ANP but
ith apparent less hypotension. The beneficial properties of
D-NP will be tested in future studies in models of
xperimentally induced heart failure.
onclusions
n summary, we report the design, synthesis, and in vivo
ardiorenal actions of a chimeric natriuretic peptide
D-NP that represents a fusion peptide of the full-length
2-AA structure of CNP together with the 15-AA
-terminus of DNP. Specifically, CD-NP is natriuretic and
iuretic, GFR enhancing, renin inhibiting, and unloads the
ormal heart, with less hypotensive properties when com-
ared with BNP. In addition, CD-NP in vitro possesses
GMP-activating and antiproliferative properties in CFs.
s CD-NP contains the native CNP peptide, which acti-
ates NPR-B, the therapeutic potential of CD-NP is made
ighly relevant by recent reports that document the down-
1egulation of the NPR-A receptor in the heart and kidney in
uman and experimental heart failure (45,46). Our findings
re significant and demonstrate the successful fusion of
ative CNP with an AA sequence taken from the
-terminus of DNP producing a chimera that now pos-
esses clinically relevant renal actions with minimal hypo-
ensive actions and favorable cardiovascular and humoral
roperties. These properties are especially attractive in acute
ardiorenal syndromes such as AHF and AMI. Further
tudies in experimental models of cardiorenal disease and
ltimately in human disease states will answer the question
f whether this strategy will indeed yield new efficacious and
afe drugs.
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